Dexcom schedules October 29 results for Dexcom stock

Published on 10/20/2026 at 18:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 1.31 billion, up 13.1 percent year over year. Dexcom stock costs EUR 75.90 on October 20, 2026 after the Xetra close.

Reporting date October 29, 2026

Dexcom scheduled its third-quarter 2026 results for October 29, 2026.
Second-quarter revenue reached USD 1.31 billion, up 13.1 percent year over year.
Dexcom stock was at EUR 75.90 at Lang & Schwarz on October 20, 2026 at 6:33 p.m. CEST.
The stock traded at USD 85.40 on Nasdaq at 12:39 p.m. ET on October 20, 2026.

NASDAQ-Tradingfloor dramatisch beleuchtet, Händler, Bildschirme mit Gesundheitscharts — Dexcom Inc. Börsen-Editorial zeigt dynamischen NASDAQ-Tradingfloor mit Gesundheitssektor-Charts für Aktionäre ISIN US2521311074, Illustration mit AI erstellt.

DexCom, Inc. (ISIN US2521311074) plans to release its third-quarter 2026 results on October 29, 2026, making the next earnings report the key date for Dexcom stock. The company also scheduled a conference call for 4:30 p.m. ET, according to Dexcom. At Lang & Schwarz, the stock was trading at EUR 75.90 on October 20, 2026 at 6:33 p.m. CEST, after the Xetra close.

Second-quarter growth sets the baseline

DexCom reported second-quarter revenue of USD 1.31 billion, up 13.1 percent from the year-earlier period. Quarterly earnings per share reached USD 0.70 against a USD 0.61 consensus estimate, according to MarketBeat.

The figures give the October 29 event a clear benchmark. Revenue must build on the USD 1.31 billion second-quarter base, while earnings will be measured against the prior USD 0.61 consensus comparison.

Stock remains below its yearly high

The Nasdaq-listed stock was at USD 85.40 at 12:39 p.m. ET on October 20, 2026, with a USD 32.2 billion market capitalization. Its 52-week range was USD 54.11 to USD 92.59, putting the latest US quote below the upper end of that range.

The Lang & Schwarz euro quotation provides the Germany-facing view after the Xetra session. Dexcom operates in healthcare and medical devices, with continuous glucose monitoring systems at the center of its business.

October 29 is the next checkpoint

Dexcom plans to publish third-quarter results after the US market close on October 29, 2026. Management's scheduled call begins at 4:30 p.m. ET, giving investors a second timing marker for the same release.

The company profile describes Dexcom as a medical technology business focused on continuous glucose monitoring. Its G7 and Stelo products extend the portfolio beyond the established diabetes-management market.

Price and reporting date

The immediate market frame is defined by the EUR 75.90 Lang & Schwarz quotation and the upcoming October 29 report. The next report will put the second-quarter revenue growth and earnings comparison into a new period.

The further course of trading is shown by the continuously updated real-time quote of Dexcom stock.